The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | Genomic testing in CLL
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, highlights the importance of genomic testing in chronic lymphocytic leukemia (CLL), drawing focus on fluorescence in situ hybridization (FISH) analysis, TP53 mutation screening, and testing of immunoglobin heavy chain gene (IgHV) mutational status. Dr Rosenquist then discusses how these genomic tests are an important part of treatment decision making and allow clinicians to better understand patient outcome in CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, and Roche
